Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Segment Information - Summary of Making Decisions Regarding the Allocation of Resources and to Assess Performance (Details)

v3.25.0.1
Segment Information - Summary of Making Decisions Regarding the Allocation of Resources and to Assess Performance (Details) - EUR (€)
€ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment Information [Line Items]      
Revenue € 1,104,036 € 1,085,354 € 983,680
Cost of sales 801,717 745,461 663,879
Gross Profit 302,319 339,893 319,801
Other operating income 9,091 10,423 18,850
Selling and Marketing expenses 24,853 24,978 26,086
Research and Development expenses 31,668 35,672 34,387
General and Administrative expenses 93,747 88,946 85,747
Operating Profit 161,142 200,720 192,431
Amortization and Depreciation and Impairment of PPE 80,652 78,480 64,822
External Customers      
Segment Information [Line Items]      
Revenue 1,104,036 1,085,354 983,680
Adjustments, Eliminations and Unallocated Items      
Segment Information [Line Items]      
Revenue (191,379) (168,790) (117,057)
Cost of sales (168,746) (140,196) (97,317)
Gross Profit (22,633) (28,594) (19,740)
Other operating income 57 (223) (148)
Selling and Marketing expenses 415 60 11,369
Research and Development expenses 1,068 599 2,676
General and Administrative expenses 13,530 10,998 (2,500)
Operating Profit (37,589) (40,474) (31,433)
Amortization and Depreciation and Impairment of PPE 1,097 (661) (1,170)
Adjustments, Eliminations and Unallocated Items | Inter-Segment      
Segment Information [Line Items]      
Revenue (191,379) (168,790) (117,057)
Biopharmaceutical and Diagnostic Solutions | Operating Segments      
Segment Information [Line Items]      
Revenue 937,779 881,337 801,237
Cost of sales 668,997 591,107 526,370
Gross Profit 268,782 290,230 274,867
Other operating income 8,926 10,630 18,985
Selling and Marketing expenses 20,847 20,970 12,287
Research and Development expenses 23,292 27,653 25,169
General and Administrative expenses 67,933 64,658 73,816
Operating Profit 165,636 187,579 182,580
Amortization and Depreciation and Impairment of PPE 75,747 75,320 62,401
Biopharmaceutical and Diagnostic Solutions | Operating Segments | External Customers      
Segment Information [Line Items]      
Revenue 933,742 879,288 799,652
Biopharmaceutical and Diagnostic Solutions | Operating Segments | Inter-Segment      
Segment Information [Line Items]      
Revenue 4,037 2,049 1,585
Engineering | Operating Segments      
Segment Information [Line Items]      
Revenue 357,636 372,807 299,500
Cost of sales 301,466 294,550 234,826
Gross Profit 56,170 78,257 64,674
Other operating income 108 16 13
Selling and Marketing expenses 3,591 3,948 2,430
Research and Development expenses 7,308 7,420 6,542
General and Administrative expenses 12,284 13,290 14,431
Operating Profit 33,095 53,615 41,284
Amortization and Depreciation and Impairment of PPE 3,808 3,821 3,591
Engineering | Operating Segments | External Customers      
Segment Information [Line Items]      
Revenue 170,294 206,066 184,028
Engineering | Operating Segments | Inter-Segment      
Segment Information [Line Items]      
Revenue 187,342 166,741 115,472
Total Segments | Operating Segments      
Segment Information [Line Items]      
Revenue 1,295,415 1,254,144 1,100,737
Cost of sales 970,463 885,657 761,196
Gross Profit 324,952 368,487 339,541
Other operating income 9,034 10,646 18,998
Selling and Marketing expenses 24,438 24,918 14,717
Research and Development expenses 30,600 35,073 31,711
General and Administrative expenses 80,217 77,948 88,247
Operating Profit 198,731 241,194 223,864
Amortization and Depreciation and Impairment of PPE 79,555 79,141 65,992
Total Segments | Operating Segments | External Customers      
Segment Information [Line Items]      
Revenue 1,104,036 1,085,354 983,680
Total Segments | Operating Segments | Inter-Segment      
Segment Information [Line Items]      
Revenue € 191,379 € 168,790 € 117,057